This review highlights thalassemia's complications and evolving treatment options, suggesting new insights into management.
Thalassemia is among the most common inherited hemoglobin disorders worldwide, caused by mutations that impair the production of alpha or beta globin chains, resulting in chronic hemolytic anemia and significant morbidity. Advances in supportive care, such as regular blood transfusions and iron chelation therapy, have dramatically improved survival, yet iron overload, cardiac failure, endocrine dysfunction, and infections remain major complications. This review summarizes the current understanding of the genetic basis, pathophysiology, diagnosis, and evolving treatment options of thalassemia.
No takes yet. Share an insight, caveat, or question.
Suad M. Jatal (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: